Showing 2621-2630 of 3223 results for "".
- Atsena Therapeutics Announces Opening of New Office and Laboratory Space in North Carolina’s Research Trianglehttps://modernod.com/news/atsena-therapeutics-announces-opening-of-new-office-and-laboratory-space-in-north-carolinas-research-triangle/2480994/Atsena Therapeutics announced the opening of its new office and laboratory in the Alexandria Center for Advanced Technologies–Research Triangle. The occasion was celebrated during a ribbon-cutting ceremony yesterday. The new state-of-the-art facility consist
- Phase 4 Paladin Study Confirms Safety of Iluvien Treatment and Reduced Burden of Care For DME Patientshttps://modernod.com/news/paladin-phase-4-study-confirms-safety-of-durable-iluvien-treatment-and-reduces-burden-of-care-for-dme-patients/2480992/Alimera Sciences announced that the PALADIN phase 4 study confirms the safety of Iluvien (fluocinolone acetonide intravitreal implant) 0.19 mg sustained release intravitreal implant and provides a durable treatment option that reduces the frequency of recurrence for patients wit
- Eyenovia Provides Manufacturing Update and Announces Appointment of Bren Kern as SVP of Manufacturing and Operationshttps://modernod.com/news/eyenovia-provides-manufacturing-update-and-announces-appointment-of-bren-kern-as-svp-of-manufacturing-and-operations/2480971/Eyenovia provided an update on its expanded manufacturing capabilities and also announced the appointment of Bren Kern as Senior Vice President of Manufacturing and Operations. The company announced that its new manufacturing facility in Redwood City, Cal
- Zeiss Ventures Invests in Morrow Eyewearhttps://modernod.com/news/zeiss-ventures-invests-in-morrow-eyewear/2480961/Zeiss Ventures has invested in Morrow, a high-tech start-up from Belgium developing autofocal glasses that allow people to switch between near vision and distance vision at the touch of a button. The innovative liquid crystal technology is embedded between two ultra-precise, thin-c
- Global Data: Increasing Cataract Surgical Rates Will Drive Artificial Lenses Market to Reach $4.7 Billion by 2030https://modernod.com/news/global-data-increasing-cataract-surgical-rates-will-drive-artificial-lenses-market-to-reach-47-billion-by-2030/2480953/The global market for IOLs is forecast by GlobalData to steadily grow from $4.3 billion in 2021 to $4.7 billion by the end of the decade. The data and analytics company notes that this growth is primarily driven by the growing capacity of many hospitals and clinics across all regions to perform m
- Harrow Health Announces Launch of Iopidine 1% and Maxitrol in the United Stateshttps://modernod.com/news/harrow-health-announces-launch-of-iopidine-1-and-maxitrol-in-the-united-states/2480929/Harrow Health announced the completion of the transfer to Harrow of the new drug applications (NDAs) of recently acquired, FDA-approved ophthalmic medicines, Iopidine 1%, Maxitrol 3.5mg/10,000 units/0.1%, and Moxeza 0.5%. Harrow also announced that Iopidine 1% and Maxitrol are
- Nanodropper Announces Growth in Partnerships and Availabilityhttps://modernod.com/news/nanodropper-announces-increases-in-partnerships-and-availability/2480921/Nanodropper, a volume-reducing adaptor for eye drop bottles, announced major growth over the last 12 months, including an 832% increase in clinic partnerships, expanding to more than 840 clinic locations since June of 2021. Nanodropper has also more than doubled its team as it finalized rese
- Nacuity Pharmaceuticals Announces $16.5 Million Series B Financing Led by Foundation Fighting Blindness & RD Fundhttps://modernod.com/news/nacuity-pharmaceuticals-announces-165-million-series-b-financing-led-by-foundation-fighting-blindness-rd-fund/2480913/Nacuity Pharmaceuticals announced the closing of a $16.5 million Series B financing led by Foundation Fighting Blindness and its venture arm RD Fund. Additional existing investors also participated in the round. Proceeds from the financing will be used to support the advanc
- Eyevensys Recaps Highlights from Investigator Meeting and Presentations at ARVOhttps://modernod.com/news/eyevensys-recaps-highlights-from-investigator-meeting-and-presentations-at-arvo/2480854/Eyevensys provided highlights from the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Conference in Denver, Colorado. In addition to its participation in the event, Eyevensys also held a successful meeting with principal investigators involved in its clinical trials
- Tarsus Announces Positive Topline Data from Saturn-2 Phase 3 Trial of TP-03 for the Treatment of Demodex Blepharitishttps://modernod.com/news/tarsus-announces-positive-topline-data-from-saturn-2-phase-3-the-second-pivotal-trial-of-tp-03-for-the-treatment-of-demodex-blepharitis/2480827/Tarsus Pharmaceuticals announced that TP-03 (lotilaner ophthalmic solution, 0.25%) met the primary endpoint and all secondary endpoints in the Saturn-2 pivotal phase 3 trial with a favorable safety profile, reinforcing its ability to resolve Demodex blepharitis. With these